Comparing Perrigo (NYSE:PRGO) & Inhibitor Therapeutics (OTCMKTS:INTI)

Perrigo (NYSE:PRGO) and Inhibitor Therapeutics (OTCMKTS:INTI) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, valuation and institutional ownership.

Earnings & Valuation

This table compares Perrigo and Inhibitor Therapeutics’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.43 billion	0.85	-$12.70 million	($0.07)	-395.57
Inhibitor Therapeutics	N/A	N/A	-$3.03 million	($0.01)	-6.90

Inhibitor Therapeutics has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Inhibitor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Perrigo and Inhibitor Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Perrigo	-2.81%	6.79%	2.99%
Inhibitor Therapeutics	N/A	-58.88%	-36.02%

Analyst Recommendations

This is a summary of recent ratings for Perrigo and Inhibitor Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	0	0	3	0	3.00
Inhibitor Therapeutics	0	0	0	0	N/A

Perrigo currently has a consensus target price of $39.33, suggesting a potential upside of 42.05%. Given Perrigo’s higher probable upside, analysts plainly believe Perrigo is more favorable than Inhibitor Therapeutics.

Risk & Volatility

Perrigo has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, Inhibitor Therapeutics has a beta of -0.64, meaning that its share price is 164% less volatile than the S&P 500.

Insider & Institutional Ownership

95.9% of Perrigo shares are held by institutional investors. 0.7% of Perrigo shares are held by company insiders. Comparatively, 4.6% of Inhibitor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Perrigo beats Inhibitor Therapeutics on 7 of the 12 factors compared between the two stocks.

About Perrigo

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.